Literature DB >> 8151270

Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.

F Bissuel1, F Bruneel, F Habersetzer, D Chassard, L Cotte, M Chevallier, J Bernuau, J C Lucet, C Trepo.   

Abstract

We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI). Clinical manifestations including vomiting, diarrhoea and dyspnoea were identical in both cases. Biological data mainly revealed hepatic failure and lactic acidosis. Histological examination of liver biopsies showed diffuse microvesicular steatosis. The outcome was fatal in both patients. The only comparable case previously reported (Lai et al., 1991) showed close similarities in the clinical, biological and histological manifestations with microvesicular steatosis. This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients. This toxic effect may be added to the list of potential adverse events occurring during ddI therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8151270     DOI: 10.1111/j.1365-2796.1994.tb01088.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  14 in total

1.  Hyperlactatemia and human immunodeficiency virus infection: lessons from the era of antiretroviral monotherapy.

Authors:  Patrick Chariot; Nacer Bourokba; Isabelle Monnet; Romain Gherardi
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Symptomatic hyperlactatemia in an HIV-positive patient: a case report and discussion.

Authors:  Tony Antoniou; Thea Weisdorf; Kevin Gough
Journal:  CMAJ       Date:  2003-01-21       Impact factor: 8.262

Review 3.  Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy.

Authors:  Phyllis C Tien
Journal:  Curr Atheroscler Rep       Date:  2015-12       Impact factor: 5.113

4.  Acute hepatic failure and lactate acidosis associated with antiretroviral treatment for HIV.

Authors:  Robert O Koch; Ivo W Graziadei; Robert Zangerle; Nikolaus Romani; Hans Maier; Wolfgang Vogel
Journal:  Wien Klin Wochenschr       Date:  2003-02-28       Impact factor: 1.704

5.  Dideoxyinosine-induced pancreatitis in human immunodeficiency virus-infected children.

Authors:  T L Levin; W E Berdon; H B Tang; J O Haller
Journal:  Pediatr Radiol       Date:  1997-02

6.  Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors.

Authors:  Gabriel Birkus; Michael J M Hitchcock; Tomas Cihlar
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

Review 7.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

Review 8.  Adverse effects of antiretroviral therapy for HIV infection.

Authors:  Valentina Montessori; Natasha Press; Marianne Harris; Linda Akagi; Julio S G Montaner
Journal:  CMAJ       Date:  2004-01-20       Impact factor: 8.262

9.  In vivo assessment of mitochondrial toxicity of metacavir in Rhesus monkeys after three months of intravenous administration.

Authors:  Wen Zeng; An-chun Cheng; Zheng-li Chen; Qi-hui Luo; Yu-bo Sun; Zhan Li; Feng-jun Bi
Journal:  Acta Pharmacol Sin       Date:  2009-11-16       Impact factor: 6.150

Review 10.  Hepatotoxicity of antiretrovirals: incidence, mechanisms and management.

Authors:  Marina Núñez; Vincent Soriano
Journal:  Drug Saf       Date:  2005       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.